InspireMD reports Q2 revenue up 9.6% to $1.65M; secures up to $113.6M private placement

InspireMD, Inc.

2023-Q2 EPS reported -$0.64 revenue$2,888,000

Closed transformational private placement: $42.2M upfront, up to $71.4M additional on milestone warrants.
Completed enrollment in C-Guardians IDE trial; anticipates PMA submission in H2 2024.
Q2 CGuard EPS revenue $1.65M (+9.6% YoY); units sold 2,804 (+7.8% YoY).
Net loss $5.08M ($0.24 per share) vs $4.64M ($0.59) in Q2 2022.
Cash $47M as of June 30, up from $17.8M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported the six months ended June 30, 2023 results: revenue $2,888,000, net income $9,333,000, EPS $0.64 per basic and diluted share.

Period: the six months ended June 30, 2023
Revenue: $2,888,000
Net income: $9,333,000
EPS: $0.64 per basic and diluted share
Result: reported results

Exact text from the filing

after deducting transaction expenses. Financial Results for the Six Months ended June 30, 2023 For the six months ended June 30, 2023, revenue increased by $174,000, or 6.4%, to $2,888,000, from $2,714,000 during the six months ended June 30, 2022. This increase was predominantly driven by a 8.3% increase in sales volume of CGuard EPS from $2,666,000 during the

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported the three months ended June 30, 2023 results: revenue $1,649,000, net income $5,077,000, EPS $0.24 per basic and diluted share.

Period: the three months ended June 30, 2023
Revenue: $1,649,000
Net income: $5,077,000
EPS: $0.24 per basic and diluted share
Result: reported results

Exact text from the filing

performed with its CGuard Prime CAS stent delivery platform as part of C-Guardians trial enrollment. ● Generated record CGuard revenue for the second quarter 2023 of $1,649,000, a 9.6 % increase over the same period in 2022 and a 33% increase over the first quarter of 2023. ● Sold 2,804 CGuard EPS stent systems in the second quarter of 2023, as compared

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.